Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Azacitidine treatment toxicities

Rena Buckstein • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine

Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, discusses some of the toxicities associated with azacitidine in the treatment of higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Rena Buckstein

2:21
Unmet needs in LR-MDS: RBC transfusion-dependence
Rena Buckstein • 10 Dec 2023
0:47
Screening for CHIP to detect potential TMNs in cancer treatment
Rena Buckstein • 10 Dec 2023
1:18
How our expanding knowledge of pre-malignant conditions may impact clinical decision-making
Rena Buckstein • 10 Dec 2023
3:24
The impact of CHIP on clinical outcomes in older patients with lymphoma undergoing chemotherapy
Rena Buckstein • 10 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals